The National Health Service (NHS) in England has launched the world's first liquid biopsy blood test, which analyzes circulating tumor DNA to identify genetic mutations in lung and breast cancers. This test allows for faster treatment customization, with trials showing results are available 16 days earlier than traditional methods, saving the NHS around £11 million a year on lung cancer care.